Waldenstrom's Macroglobulinemia Clinical Trial
Official title:
Phase 1/2 Open-Label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 90% of the patients with Waldenström's macroglobulinemia. MYD88 is a key linker protein in the signaling pathway of Toll Like Receptors (TLRs) 7, 8, and 9, and IMO-8400 is an oligonucleotide specifically designed to inhibit TLRs 7,8, and 9. The scientific hypothesis for use of IMO-8400 to treat patients with Waldenström's macroglobulinemia depends on the inhibition of mutant MYD88 signaling in the TLR pathway, thereby interrupting the proliferation of cell populations responsible for the propagation of the disease.
Eligible subjects will be enrolled and assigned to escalating dose cohorts. Treatment will be administered by subcutaneous injection. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02566265 -
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
|
Phase 2 | |
Completed |
NCT00422656 -
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00165295 -
Sildenafil Citrate in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00150462 -
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
|
Phase 1 | |
Terminated |
NCT00142168 -
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Suspended |
NCT02439138 -
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
|
Phase 2 | |
Completed |
NCT01470196 -
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00250926 -
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
|
Phase 2 | |
Terminated |
NCT03225716 -
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
|
Phase 1 | |
Terminated |
NCT01744912 -
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT02363439 -
Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
|
Phase 1/Phase 2 | |
Completed |
NCT00976248 -
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Terminated |
NCT00575965 -
Simvastatin in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00919139 -
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
|
N/A | |
Completed |
NCT01614821 -
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Active, not recruiting |
NCT01078974 -
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 1 | |
Completed |
NCT00481871 -
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00142116 -
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00807677 -
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01046006 -
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
|
Phase 2 |